Tofenacin Explained

Tofenacin is an antidepressant drug with a tricyclic-like structure which was developed and marketed in the United Kingdom and Italy in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia (now part of Astellas Pharma).^{[1] [2] [3]} It acts as a serotonin-norepinephrine reuptake inhibitor,^[4] and based on its close relation to orphenadrine, may also possess anticholinergic and antihistamine properties. Tofenacin is also the major active metabolite of orphenadrine and likely plays a role in its beneficial effects against depressive symptoms seen in Parkinson's disease patients.^{[5] [6]}

See also

• Clemastine
• Orphenadrine
• Tiazesim

Notes and References

1. Book: Index Nominum 2000: International Drug Directory . 19 May 2012 . 2000 . Taylor & Francis US . 978-3-88763-075-1 . 1041.
2. Book: Buckingham J . Dictionary of organic compounds: Chemical Abstracts Service registry number index . 19 May 2012 . 1996 . CRC Press . 978-0-412-54090-5 . 6074.
3. Book: Pharmaceutical Manufacturing Encyclopedia . 3rd . 19 May 2012 . Elsevier . 978-0-8155-1526-5 . 3268. 2013-01-15.
4. Book: van Dijk J, Hartog J, Hillen FC . Non-Tricyclic Antidepressants. Ellis GP, West GB . Progress in Medicinal Chemistry . https://books.google.com/books?id=YN9YWk4T4fwC&pg=PA284 . 19 May 2012 . 1 January 1978 . Elsevier . 978-0-7204-0655-9 . 284.
5. Capstick N, Pudney H . A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy . The Journal of International Medical Research . 4 . 6 . 435–440 . 1976 . 800383 . 10.1177/030006057600400610 . 40083513 .
6. Altamura AC, Mauri MC, De Novellis F, Percudani M, Vampini V . Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine . Pharmacopsychiatry . 22 . 6 . 246–249 . November 1989 . 2616635 . 10.1055/s-2007-1014608 . 39693625 .